Philanthropies as partners for drug development in public–private partnerships
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 1
Abstract
Disease-focused philanthropic organizations play an increasing role in the strategy and conduct of biomedical research, with many focusing on drug development for specific diseases and patient populations. More and more they not only provide resources and expertise, but also take active part managing the strategy and objectives of targeted research programs, using approaches such as venture philanthropy. Many also lead and participate in public–private partnerships. One example is the partnership between the Polycystic Kidney Disease (PKD) Foundation and the Critical Path Institute (C-Path) which brings together several pharmaceutical companies and academic institutions to develop new broadly-used biomarkers. Another case is the partnership between JDRF (formerly known as the Juvenile Diabetes Research Foundation) and the Innovative Medicines Initiative (IMI), involving financial support of the IMIDIA project (Innovative Medicines Initiative for Diabetes) which is focused on improving beta-cell function and identifying biomarkers for diabetes treatment monitoring. These examples show that in addition to providing financial support and expertise, philanthropic foundations are also in a unique position to coordinate the patient and research communities to enable and accelerate specific medicines development projects.
Authors and Affiliations
Mark D. Lim, Martha A. Brumfield and Michel Goldman
Keywords
Related Articles
- EP ID EP679255
- DOI -
- Views 154
- Downloads 0
The Predictive Safety Testing Consortium: safety biomarkers, collaboration, and qualification
The Predictive Safety Testing Consortium (PSTC) is one of nine consortia comprising the Critical Path Institute (C-Path), a non-profit organisation launched in 2005 and dedicated to playing the role of a catalyst in the...
Japanese initiative for education in pharmaceutical medicine and clinical research training
Development of new medicines has become increasingly difficult with less possibility of success in seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection a...
Philanthropies as partners for drug development in public–private partnerships
Disease-focused philanthropic organizations play an increasing role in the strategy and conduct of biomedical research, with many focusing on drug development for specific diseases and patient populations. More and more...
HDL therapies — past, present and future
For a number of years, high-density lipoprotein (HDL) has been recognized to have an athero-protective role by promoting reverse lipid transport, a process facilitating the cholesterol efflux from atherosclerotic plaques...
Determination of Genistin Content in Flemingia philippinensis Merr. et Rolfe by High Performance Liquid Chromatography (HPLC)
To set up the HPLC method in determination of the genistin content in Flemingia philippinensis Merr. et Rolfe. Method: Extract and filter the crushed Flemingia philippinensis Merr. et Rolfe that has been soaked in methan...